Cargando…

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses

BACKGROUND: Most of the millions of people that are vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), have previously been infected by related circulating human coronaviruses (hCoVs) causing common colds and w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawrenz, Jan, Xie, Qinya, Zech, Fabian, Weil, Tatjana, Seidel, Alina, Krnavek, Daniela, van der Hoek, Lia, Münch, Jan, Müller, Janis A, Kirchhoff, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807272/ https://www.ncbi.nlm.nih.gov/pubmed/35079775 http://dx.doi.org/10.1093/cid/ciac057

Ejemplares similares

Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor
por: Weil, Tatjana, et al.
Publicado: (2022)

Determinants of species-specific utilization of ACE2 by human and animal coronaviruses
por: Wang, Qingxing, et al.
Publicado: (2023)

BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
por: Seidel, Alina, et al.
Publicado: (2022)

Endogenous IFITMs boost SARS-coronavirus 1 and 2 replication whereas overexpression inhibits infection by relocalizing ACE2
por: Xie, Qinya, et al.
Publicado: (2023)

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
por: Groß, Rüdiger, et al.
Publicado: (2021)

Epidemiology of Seasonal Coronaviruses: Establishing the Context for the Emergence of Coronavirus Disease 2019
por: Nickbakhsh, Sema, et al.
Publicado: (2020)

Seroepidemiology of the Seasonal Human Coronaviruses NL63, 229E, OC43 and HKU1 in France
por: De Thoisy, Alix, et al.
Publicado: (2023)

Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
por: Upasani, Vinit, et al.
Publicado: (2023)

Spike residue 403 affects binding of coronavirus spikes to human ACE2
por: Zech, Fabian, et al.
Publicado: (2021)

Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant
por: Hwa, Shi-Hsia, et al.
Publicado: (2022)

Human seasonal coronavirus neutralization and COVID‐19 severity
por: Wells, David A., et al.
Publicado: (2022)

Persistence of Neutralizing Antibodies and Clinical Protection up to 12 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the Elderly
por: Collarino, Rocco, et al.
Publicado: (2022)

Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days
por: Haymond, Amanda, et al.
Publicado: (2021)

Contribution of Coronavirus-Specific Immunoglobulin G Responses to Complement Overactivation in Patients with Severe Coronavirus Disease 2019( )
por: Castanha, Priscila M S, et al.
Publicado: (2022)

Opioid Injection-Associated Bacterial Infections in England, 2002–2021: A Time Series Analysis of Seasonal Variation and the Impact of Coronavirus Disease 2019
por: Lewer, Dan, et al.
Publicado: (2023)

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
por: Muecksch, Frauke, et al.
Publicado: (2020)

Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Magnus, Maria C, et al.
Publicado: (2022)

Delayed and Attenuated Antibody Responses to Coronavirus Disease 2019 Vaccination With Poor Cross-Variant Neutralization in Solid-Organ Transplant Recipients—A Prospective Longitudinal Study
por: Liew, May Y, et al.
Publicado: (2023)

Dying at Home Due to Coronavirus Disease 2019
por: Edwards, Jessie K, et al.
Publicado: (2022)

Human Coronavirus NL63 Is Not Detected in the Respiratory Tracts of Children with Acute Kawasaki Disease
por: Shimizu, Chisato, et al.
Publicado: (2005)

Racial, Ethnic, and Geographic Disparities in Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Test Positivity in North Carolina
por: Turner, Nicholas A, et al.
Publicado: (2020)

Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses
por: Petrie, Joshua G, et al.
Publicado: (2021)

Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya
por: Kiyuka, Patience K, et al.
Publicado: (2018)

High Infection Secondary Attack Rates of Severe Acute Respiratory Syndrome Coronavirus 2 in Dutch Households Revealed by Dense Sampling
por: Reukers, Daphne F M, et al.
Publicado: (2021)

Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
por: Klingler, Jéromine, et al.
Publicado: (2020)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Coronavirus Disease 2019–Associated Invasive Fungal Infection
por: Baddley, John W, et al.
Publicado: (2021)

Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Reported Coronavirus Disease 2019 Cases in US Children, August 2020–May 2021
por: Couture, Alexia, et al.
Publicado: (2022)

SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
por: Seidel, Alina, et al.
Publicado: (2023)

Ethnic Differences in Coronavirus Disease 2019 Hospitalization and Hospital Outcomes in a Multiethnic Population in the Netherlands
por: Collard, Didier, et al.
Publicado: (2022)

Recently Discovered Human Coronaviruses
por: Wevers, Brigitte A., et al.
Publicado: (2009)

Mid-regional Proadrenomedullin Biomarker Predicts Coronavirus Disease 2019 Clinical Outcomes: A US-Based Cohort Study
por: Atallah, Natalie J, et al.
Publicado: (2022)

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Crawford, Katharine H D, et al.
Publicado: (2020)

Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies
por: Khatri, Akshay, et al.
Publicado: (2021)

Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study
por: Yamamoto, Shohei, et al.
Publicado: (2021)

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
por: Baksh, Sheriza N, et al.
Publicado: (2023)

Inactivation of surrogate coronaviruses on hard surfaces by health care germicides
por: Hulkower, Rachel L., et al.
Publicado: (2011)

Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019
por: Mandell, Lionel A, et al.
Publicado: (2022)

Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate
por: Clancy, Cornelius J, et al.
Publicado: (2022)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vapj9923ol8vaqdvh5ptldj222